Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression ... The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato ...

The UK agency declined to recommend NHS funding for Spravato (esketamine) nasal spray in 2020 – following its approval as an add-on therapy for people with serious depression who don’t respond ...